AKERO THERAPEUTICS INC's ticker is AKRO and the CUSIP is 00973Y108. A total of 157 filers reported holding AKERO THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.70 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,609,220 | +35.4% | 51,586 | +24.9% | 0.01% | +60.0% |
| Q2 2023 | $1,927,643 | +67.3% | 41,286 | +37.1% | 0.01% | +66.7% |
| Q1 2023 | $1,152,353 | -26.6% | 30,119 | +5.1% | 0.00% | -40.0% |
| Q4 2022 | $1,571,006 | +148.2% | 28,668 | +54.3% | 0.01% | +150.0% |
| Q3 2022 | $633,000 | +268.0% | 18,581 | +2.3% | 0.00% | – |
| Q2 2022 | $172,000 | -63.6% | 18,166 | -45.4% | 0.00% | -100.0% |
| Q1 2022 | $473,000 | -32.8% | 33,300 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $704,000 | -5.4% | 33,300 | 0.0% | 0.00% | -50.0% |
| Q3 2021 | $744,000 | -9.9% | 33,300 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $826,000 | +56.4% | 33,300 | +83.0% | 0.00% | +100.0% |
| Q1 2021 | $528,000 | +7.8% | 18,200 | -4.2% | 0.00% | 0.0% |
| Q4 2020 | $490,000 | +23.4% | 19,000 | +47.3% | 0.00% | 0.0% |
| Q3 2020 | $397,000 | +23.7% | 12,900 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $321,000 | +17.6% | 12,900 | 0.0% | 0.00% | 0.0% |
| Q1 2020 | $273,000 | – | 12,900 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ATP Life Science Ventures, L.P. | 5,830,203 | $179,512,000 | 24.20% |
| venBio Partners LLC | 2,444,311 | $75,260,000 | 11.44% |
| Versant Venture Management, LLC | 777,727 | $23,946,000 | 4.38% |
| Redmile Group, LLC | 2,336,357 | $71,936,000 | 1.32% |
| Vivo Capital, LLC | 571,833 | $17,607,000 | 1.02% |
| Cormorant Asset Management, LP | 859,550 | $26,466,000 | 1.02% |
| Boxer Capital, LLC | 831,495 | $25,602,000 | 0.88% |
| Integral Health Asset Management, LLC | 85,000 | $2,617,000 | 0.80% |
| EAM Global Investors LLC | 49,718 | $1,531,000 | 0.56% |
| Crawford Lake Capital Management, LLC | 43,826 | $1,349,000 | 0.56% |